home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  STRUCTURE-BASED DRUG DESIGN  
  December 06, 2000

Biotechnology

 
     
  Cambridge Healthtech Institute, Cambridge, Massachusetts
April 11-12, 2001


The wealth of information made available through efforts in structural genomics and advances in computation has allowed structure-based drug design to emerge as a valuable tool in medicinal chemistry. In the past combinatorial chemistry, coupled with high-throughput approaches, shifted attention away from the more structure-based methods. Large-scale determination of protein structures is reversing the drug discovery process by starting with the protein structure and using it to identify and design new ligands. It is the integration of structure-based methods, virtual screening, and combinatorial chemistry that will provide the basis for more efficient drug design in the future, significantly reducing the time of the design cycle and the cost per marketed drug.


 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers: Dr. David Bailey, De Novo Pharmaceuticals Ltd.
Dr. Mark Murcko, Vertex Pharmaceuticals, Inc.
Dr. Tomi K. Sawyer, ARIAD Pharmaceuticals, Inc.
Dr. John H. van Drie, Pharmacia & Upjohn, Inc.
Dr. Christian Lemmen, DuPont Pharmaceuticals Company
Dr. Hans-Joachim Boehm, Hoffmann-La Roche Ltd.


 
Deadline for Abstracts: March 9, 2001
 
Registration: Available on-line
E-mail: jlaakso@healthtech.com
 
  Posted by:   Jennifer Laakso  
Host: wks217.healthtech.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.